A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

• Status: Not yet recruiting
• Trial end date: 2022-01-01
• Target enrollment: 108
• Participant gender: All

Summary

To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients with inoperable pancreatic cancer confers survival benefit when compared to patients receiving standard medical care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Criteria

Inclusion Criteria:

• Patients above 18 years of age.

• A cytological / histological diagnosis of inoperable PDAC based on multidisciplinary review of cross-sectional imaging and cytology / histology results.

• Patients ought to be fit enough to be considered for the study (ECOG performance status 0, 1 or 2)

• Patients who have commenced chemotherapy are not excluded from the study

• Patients capable of giving informed consent

• Negative blood pregnancy test for women of childbearing potential

• Willingness and ability to comply with all protocol requirements including scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria:

• ECOG performance status 3 or 4

• Life expectancy less than 3 months (including liver metastases, carcinomatosis)

• Prior investigational drugs within the last 30 days

• Known infection with human immunodeficiency virus (HIV)